Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
No matching data
Latest Views
Latest Views
Trending Topics
To quickly learn market dynamics and follow market focuses in 15 min.
In the world of mankind, there will not be a statement without any position, nor a remark without any purpose.
Inflation, exchange rates, and the economy shape the policy decisions of central banks; the attitudes and words of central bank officials also influence the actions of market traders.
Money makes the world go round and currency is a permanent commodity. The forex market is full of surprises and expectations.
Top Columnists
Enjoy exciting activities, right here at FastBull.
The latest breaking news and the global financial events.
I have 5 years of experience in financial analysis, especially in aspects of macro developments and medium and long-term trend judgment. My focus is maily on the developments of the Middle East, emerging markets, coal, wheat and other agricultural products.
BeingTrader chief Trading Coach & Speaker, 8+ years of experience in the forex market trading mainly XAUUSD, EUR/USD, GBP/USD, USD/JPY, and Crude Oil. A confident trader and analyst who aims to explore various opportunities and guide investors in the market. As an analyst I am looking to enhance the trader’s experience by supporting them with sufficient data and signals.
Latest Update
Risk Warning on Trading HK Stocks
Despite Hong Kong's robust legal and regulatory framework, its stock market still faces unique risks and challenges, such as currency fluctuations due to the Hong Kong dollar's peg to the US dollar and the impact of mainland China's policy changes and economic conditions on Hong Kong stocks.
HK Stock Trading Fees and Taxation
Trading costs in the Hong Kong stock market include transaction fees, stamp duty, settlement charges, and currency conversion fees for foreign investors. Additionally, taxes may apply based on local regulations.
HK Non-Essential Consumer Goods Industry
The Hong Kong stock market encompasses non-essential consumption sectors like automotive, education, tourism, catering, and apparel. Of the 643 listed companies, 35% are mainland Chinese, making up 65% of the total market capitalization. Thus, it's heavily influenced by the Chinese economy.
HK Real Estate Industry
In recent years, the real estate and construction sector's share in the Hong Kong stock index has notably decreased. Nevertheless, as of 2022, it retains around 10% market share, covering real estate development, construction engineering, investment, and property management.
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
View All
No data
Not Logged In
Log in to access more features
FastBull Membership
Not yet
Purchase
Log In
Sign Up
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
The Dogs of the Dow is a long standing wall street strategy for investing in the stock market that involves purchasing the 10 highest yielding Dow Jones Industrial Average stocks. The DJIA is a stock market index that consists of 30 large publicly traded companies listed on the New York Stock Exchange and the NASDAQ 100 Index .
The Dogs of the Dow strategy is based on the idea that the high dividend yield of these stocks indicates that they may be undervalued by the market and are likely to outperform in the future. The strategy involves rebalancing the portfolio at the end of each year to ensure that it still includes the 10 highest yielding DJIA stocks.
The Dogs of the Dow strategy has been popular with investors as a way to potentially generate income and outperform the market. However, like all investment strategies, it carries risks and may not always be successful.
So, what are the 10 highest yielding stocks in the Dow right now? We can use the Stock Screener to find all the Dow stocks and include a column for Annual dividend yield.
Then for the results, we select Filter View and sort by Dividend Yield.
So our 10 Dogs of the Dow for 2024 are:
International Business Machines
As shown in the above table, there are some very healthy dividend yields on offer. One way to further enhance this yield is by selling covered calls.
Some people like to sell monthly covered calls, but that can require ongoing maintenance and monitoring. Today, we’re going to look at a yearly covered call for those that like a more set and forget approach.
Amgen Yearly Covered Call Example
Let’s use the third stock on the list, Amgen, and look at an example.
Buying 100 shares of AMGN would cost around $26,354. The December 19, 2025, call option with a strike price of $280 was trading yesterday for around $21.10, generating $2,110 in premium per contract for covered call sellers.
Selling the call option generates an income of 8.71% in 358 days, equalling around 8.88% annualized.
That assumes the stock stays exactly where it is. What if the stock rises above the strike price of $280?
If AMGN closes above $280 on the expiration date, the shares will be called away at $280, leaving the trader with a total profit of $3,781 (gain on the shares plus the $2,110 option premium received). That equates to a 15.61% return, which is 15.92% on an annualized basis.
That doesn’t include dividends. AMGN is estimated to pay around $9.00 in dividends over the next 12 months which would increase the income potential by 3.40% per annum.
Let’s look at another example using Chevron.
Chevron Yearly Covered Call Example
Buying 100 shares of CVX would cost around $14,396. The December 19, 2025, call option with a strike price of $150 was trading yesterday for around $9.70, generating $970 in premium per contract for covered call sellers.
Selling the call option generates an income of 7.22% in 358 days, equalling around 7.37% annualized.
That assumes the stock stays exactly where it is. What if the stock rises above the strike price of $150?
If CVX closes above $150 on the expiration date, the shares will be called away at $150, leaving the trader with a total profit of $1,574 (gain on the shares plus the $970 option premium received). That equates to an 11.72% return, which is 11.95% on an annualized basis.
That doesn’t include dividends. CVX is estimate to pay around $6.52 in dividends over the next 12 months which would increase the income potential by 4.53% per annum.
Selling covered calls in 2025 on the Dogs of the Dow stocks, could be a great strategy for generating income and building long term wealth.
Please remember that options are risky, and investors can lose 100% of their investment. This article is for education purposes only and not a trade recommendation. Remember to always do your own due diligence and consult your financial advisor before making any investment decisions.
On the date of publication, Gavin McMaster did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policyhere.
More news from BarchartBy Jacob Sonenshine
Healthcare stocks have gotten crushed in 2024, and next year doesn't look much better. But there are still opportunities for investors willing to sort through the wreckage.
The Health Care Select Sector SPDR exchange-traded fund has gained 1.2% in 2024, lagging the S&P 500's 24% gain. Recent developments, including a bipartisan bill calling for insurers to separate from their pharmacy benefit management units, or PBMs, has caused pain, but the sector has been unloved for most of the last 11 months and change. Issues range from the high cost of drug development to concerns about Medicare Advantage programs.
So where should investors look? Not with those health insurers that own PBMs. Though this year has been particularly painful for CVS Health and Humana — they both have dropped 45% in 2024 — and only less so for Cigna, which has dropped 7.8%,%, Deutsche Bank analyst George Hill estimates that these companies could lose anywhere from 40% to over 50% of their operating profits if they were forced to divest their PBM assets. Forced divestitures, which would most likely happen in the form of spin offs, could also happen at fairly low valuations because they are likely worth more under these large insurers than as stand-alones. While analysts haven't quantified how much of their sales are a result of accessing patients from the companies' wider networks, there's an assumption that they'd acquire fewer patients if they were on their own.
The one exception is UnitedHealth, which has dropped 20% since its November high after the fatal shooting of its insurance CEO. Hill, along with other analysts, estimates that United's operating profit from its PBM amounts to a low single digit percentage of total operating income. He puts the number at roughly $200 million, a drop in the bucket versus the consensus estimate for total operating income of $35.7 billion this year.
Premiums revenue, however, has grown every year since at least 2010, as the company signs up millions of new, eligible Medicare advantage members every year. Analysts expect 8.7% annual growth of premiums revenue for the next three years to about $400 billion by 2027, though there have been concerns about how much that can continue given the spotlight put on premiums after the shooting. At that rate — and with some help from annual share repurchases — earnings per share could grow by about 12% annually.
The stock now looks cheap. Shares trades at 16.8 times expected earnings for the coming 12 months. Even if earnings are a couple percent lower than expected, the stock still wouldn't even trade at 18 times. The multiple is below its peak of 20.5 times this year and a wider discount to the S&P 500's 21.5 times. True, the market fears the upset from the tragic killing of United's CEO will push Congress to write other regulations, and may weigh on the valuation. But over time, earnings should grow. The stock can rise, especially if regulation isn't too stringent.
For United, "if you're a long-term shareholder, this is a good entry point," says Morningstar analyst Julie Utterback.
Elsewhere, drugmakers have failed to keep up with the market. The SPDR S&P Pharmaceuticals ETF has risen just 4.3%. With 44.2% of its holdings underwater this year. For some, disappointing drug trials have been the problem. Amgen stock is down 8.7% in 2024 after the company's obesity-drug, MariTide, showed disappointing efficacy in a trial.
That's not the same as failing and analysts believe MariTide remains viable. Patients would take it once every month or two, less frequently than most other products, and it helps patients maintain the weight they lose. Those are reasons, BMO analyst Evan Siegerman says, the drug could ultimately sell well. He says a few physicians, albeit not many, he's spoken with, say patients could use it after having used others.
That could unlock billions of dollars of additional sales for Amgen, a significant chunk versus the $34.4 billion in total revenue analysts expect this year. The market for GLP-1s is potentially above $100 billion over the long-term, and with leaders Eli Lilly and Novo Nordisk expected to combine for less than $60 billion of such sales by 2027, there's plenty of opportunity for the likes of Amgen to grab some market share. Investors will also get a 3.6% dividend yield as they wait for updates from Amgen on MariTide.
But even the winners have fallen on hard times in recent months. Eli Lilly, for instance, has gained 36% this year but is down 14% over the past three months. Much of that drop is a result of an earnings miss combined with reduced guidance, which caused the stock to tumble on Oct. 31. Other concerns, including the production of GLP-1s by compounding pharmacies haven't helped.
But Eli Lilly has rallied in recent days. Novo Nordisk's trial results for a new GLP-1 disappointed the market, good news for Eli and its Zepbound, which is expected to grow to $18 billion by 2027 from $5.1 billion this year. The drug was also shown to be effective for obstructive sleep apnea, giving the stock another boost. The government also recently said that GLP-1s are no longer in shortage, which could make the compounding problem go away.
For anyone looking to buy Lilly on the dip, this might be the chance.
Write to Jacob Sonenshine at jacob.sonenshine@barrons.com
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
The Dow Jones Industrial Average Index ($DOWI) is made up of 30 large, established companies from a variety of industries. It is frequently used as an indicator of the overall health of the U.S. stock market and economy. Here we have two Dow stocks that are stable, dividend-paying companies. As we head into the new year, savvy investors should consider adding these names to their portfolios.
Dow Stock #1: Cisco Systems
With a market cap of $234.9 billion, Cisco Systems is a global leader in networking hardware, software, and services. While its roots are in internet connectivity, its portfolio now includes cloud computing, cybersecurity, artificial intelligence, and collaboration tools.
Cisco stock is up 18% year-to-date, compared to the Dow Jones Industrial Average's nearly 15% gain.
Cisco's focus on subscription-based services and software has resulted in a more consistent revenue stream, mitigating the cyclical nature of hardware sales. While subscription-based revenue streams are beneficial in the long run, they may cause short-term revenue fluctuations if hardware sales fall, as happened in the first quarter of fiscal 2025. Product revenue fell by 9%, resulting in a 6% decline in total revenue to $13.8 billion. Adjusted earnings per share fell to $0.91 from $1.11 in the same quarter last year.
However, the remaining performance obligation (RPO), or contracted revenue to be recognized over the next 12 months, stood at $40 billion, up 15%. Furthermore, the company's deferred revenue totaled $27.5 billion in advance for products and services that have yet to be delivered.
Despite ongoing investments in portfolio expansion and AI upgrades, as well as strategic acquisitions, the company maintains a strong balance sheet with significant cash reserves and manageable debt levels. In Q1, it acquired DeepFactor, a privately held cloud-native application security company, and Robust Intelligence, a private AI security solutions provider. At the end of the quarter, cash, cash equivalents, and investments totaled $18.7 billion, with a manageable debt-to-equity ratio of 0.43x.
Cisco has a dividend yield of 2.7%, which is higher than the tech sector average of 1.4%. The forward payout ratio of 43.8% indicates that dividend payments are sustainable, with room for growth. Cisco has also increased its dividends consistently over the last 13 years.
Cisco’s commitment to returning capital to shareholders is evident in its consistent dividend payments and stock repurchase programs. In the first quarter, Cisco returned $3.6 billion to shareholders through dividends and buybacks.
Management expects revenue growth of 2% to 4% in fiscal year 2025, which is consistent with the consensus estimate of $56 billion. Adjusted earnings could fall by 2% before rising 7.5% in fiscal 2026. Cisco stock is trading at 15 times forward 2026 earnings, compared to a five-year average historical price-to-earnings multiple of 38.9x.
Overall, Cisco stock is ideal for long-term investors seeking a combination of stability, income, and moderate growth. The company's strong financial position, emphasis on high-margin software and services, and strategic investments in emerging markets such as cybersecurity and 5G make it an appealing choice.
On Wall Street, Cisco stock is a "Moderate Buy.” Of the 21 analysts covering Cisco, seven have rated it a “Strong Buy,” two have a “Moderate Buy” recommendation, and 12 suggest a “Hold.” Its mean price target of $62.63 implies the stock could go as high as 6.18% from current levels. Its Street-high estimate of $78 suggests the stock could rally as much as 32.2% over the next 12 months.
Dow Stock #2: Chevron Corporation
With roots dating back to 1879, Chevron Corporation is one of the world's oldest and largest oil and gas companies. The company is well-known for its involvement in all aspects of the energy sector, including oil and natural gas exploration, refining, and marketing.
Its business model, based on a mix of upstream and downstream operations, has helped the company weather volatile commodity price cycles and remain stable. Chevron stock has fallen 4% year-to-date, compared to the Dow's gain and the overall market gain of 26%.
In the third quarter, both upstream and downstream segments underperformed, leading to an adjusted earnings dip of 17.7% to $2.51 per share in the quarter. According to management, lower margins on refined product sales and some other tax-related headwinds caused the decrease in earnings.
However, global net oil-equivalent production increased by 7% over Q3 2023, driven by higher production in the Permian Basin (thanks to AI) and the acquisition of PDC Energy completed in 2023.
Chevron's strong balance sheet and disciplined capital allocation strategy have allowed it to maintain dividend payouts while investing in growth initiatives. Chevron has consistently increased its dividends for the past 37 years, making it a Dividend Aristocrat.
The forward payout ratio of 58.8% indicates that the company's earnings can support dividend payments, with room for dividend growth. It reported $4.7 billion in cash and cash equivalents at the end of the quarter. It also generated $5.6 billion in free cash flow during the quarter and returned $7.7 billion through dividends and share repurchases. Its low debt-to-equity ratio of 0.16x reflects its cautious approach to leverage. Chevron has an attractive dividend yield of 4.5%, compared to the energy sector's average yield of 4.2%.
Chevron's upstream operations account for the majority of its earnings, so the company intends to spend $13 billion in upstream capex and $1.2 billion in downstream capex in 2025 as part of its overall capex budget.
In addition, Chevron began several projects during the quarter, including the Anchor, Jack/St. Malo, and Tahiti fields. Management expects that these projects and upcoming project startups in 2025 will increase "U.S. Gulf of Mexico production to 300,000 barrels of net oil-equivalent per day by 2026."
Furthermore, the company intends to sell $10 billion to $15 billion of its assets by 2028, as well as make structural cost cuts of $2 billion to $3 billion by the end of 2026. These strategic initiatives may help boost Chevron's earnings in the near future.
Analysts expect Chevron's earnings to fall 20% in 2024 before rising 5.6% in 2025. On Wall Street, Chevron stock is rated a "Strong Buy." Of the 22 analysts covering Chevron, 15 recommend it as a "Strong Buy," two as a "Moderate Buy," and five as a "Hold." Its mean price target of $175.14 implies that the stock could rise by 22.5% from its current level. Its Street-high estimate of $195 indicates that the stock could rally as much as 36.4%.
While challenges persist, Chevron’s diversified business model, strong financial health, and shareholder-focused policies make it a great choice for both growth- and income-oriented investors.
On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from BarchartWhite Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.